Rabies DNA vaccine - LigoCyte/NIAID

Drug Profile

Rabies DNA vaccine - LigoCyte/NIAID

Latest Information Update: 05 Aug 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LigoCyte Pharmaceuticals; National Institute of Allergy and Infectious Diseases
  • Class Gene therapies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rabies

Most Recent Events

  • 05 Aug 2004 Discontinued - Preclinical for Rabies in USA (IM)
  • 12 Jan 2004 No development reported - Preclinical for Rabies in USA (IM)
  • 05 Oct 2001 LigoCyte has entered into a CRADA with the NIAID for development of the rabies vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top